Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Adjuvant Pembrolizumab Maintains DFS Benefit in High-Risk RCC

February 20th 2022

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Neoadjuvant Avelumab/Axitinib Combination Elicits Promising Response Rates in High-Risk RCC

February 20th 2022

The addition of the PD-L1 inhibitor avelumab to the TKI axitinib generated promising efficacy as a neoadjuvant therapy in patients with high-risk, non-metastatic clear-cell renal cell carcinoma.

Dr. Choueiri on the Follow-Up Analysis of KEYNOTE-564 in RCC

February 19th 2022

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Superior Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC

February 19th 2022

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

Lenvatinib Plus Pembrolizumab Produces Consistent Efficacy in East Asian Subset With Advanced RCC

February 19th 2022

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC

February 19th 2022

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.

Frontline Nivolumab/Cabozantinib Combo Maintains Long-Term OS Benefit in RCC

February 19th 2022

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Cabozantinib Dose Reduction Improves Survival in Patients With mRCC

February 19th 2022

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

Long-Term Data Show That Tivozanib Continues to Be Superior Vs Sorafenib in mRCC

February 19th 2022

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

Frontline Tivozanib Is Effective, Safe in Real-World Treatment of mRCC

February 19th 2022

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

Lenvatinib/Pembrolizumab Combo Effective in Advanced RCC, Regardless of Biomarker Status

February 19th 2022

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

Second-Line Cabozantinib Produces Similar Outcomes in RCC, Regardless of Frontline Immunotherapy Choice

February 19th 2022

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

Cabozantinib After Immunotherapy Failure Reassured as Safe, Feasible for mRCC

February 19th 2022

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

FDG and NaF PET/CT Imaging Prognostic for OS in Metastatic GU Cancers Treated With Cabozantinib/Nivolumab Combos

February 18th 2022

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

Dr. Munver on the Utilization of Mitomycin Gel in GU Cancers

February 14th 2022

Ravi Munver, MD, discusses the utilization of mitomycin gel in genitourinary cancers.

Metastatic Urothelial Carcinoma: Optimizing Use of Frontline Maintenance Therapy

February 9th 2022

Shared insight on the use of maintenance therapy in metastatic urothelial carcinoma with regard to PD-L1 testing and patient education.

Interpreting JAVELIN Bladder 100: Avelumab in Metastatic Urothelial Carcinoma

February 9th 2022

Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.

Immunotherapy’s Roles in Treating Metastatic Urothelial Carcinoma

February 2nd 2022

Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.

A Global View on Metastatic Urothelial Carcinoma

February 2nd 2022

Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.

Nivolumab/Cabozantinib Combo Improves Patient-Reported Outcomes Over Sunitinib in RCC

January 26th 2022

The combination of nivolumab and cabozantinib was associated with improved quality of life compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to patient-reported outcome data from the phase 3 CheckMate-9ER trial.